Neamah, A. S. (2026). Metabolic enzymes and immune receptors as emerging checkpoints in breast cancer: Mechanisms, clinical trials, and therapeutic implications. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(10), 16541-16556. https://doi.org/10.1007/s00210-026-05395-6
Παραπομπή σε μορφή Chicago (17η εκδ.)Neamah, Abbas S. "Metabolic Enzymes and Immune Receptors as Emerging Checkpoints in Breast Cancer: Mechanisms, Clinical Trials, and Therapeutic Implications." Naunyn-Schmiedeberg's Archives of Pharmacology 399, no. 10 (2026): 16541-16556. https://doi.org/10.1007/s00210-026-05395-6.
Παραπομπή σε μορφή MLA (9th εκδ.)Neamah, Abbas S. "Metabolic Enzymes and Immune Receptors as Emerging Checkpoints in Breast Cancer: Mechanisms, Clinical Trials, and Therapeutic Implications." Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 399, no. 10, 2026, pp. 16541-16556, https://doi.org/10.1007/s00210-026-05395-6.